Since antibiotic-resistant bacterial infections directly cause at least 1.27 million deaths annually, antimicrobial resistance (AMR) is a developing pandemic and a possible threat to public health in the twenty-first century. In India, a serious concern is that, nearly 60–70% of all isolates are resistant to important antibiotics as methicillin, fluoroquinolones, cephalosporins, and carbapenems. Given the critical need to tackle AMR and ongoing efforts in India for development of innovative diagnostics, the National Biopharma Mission aiming in advancing the development and/or production of diagnostics for identification and generation of antimicrobial sensitivity profiles of key antimicrobial resistant pathogens for integration within public health systems. In addition, the AMR call supports the development and clinical validation of efficient biotherapeutics and treatment options against AMR infections.
|
Therapeutic Area/ Name of Product |
Name of grantee |
Environmental and Health Risk Management Plan (EHRMP) |
|
A Phase II/III, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam/WCK 4282 vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults |
Wockhardt Limited |
|
|
Next Generation phenotypic test platform for Rapid Antimicrobial susceptibility testing |
Module Innovations Pvt Ltd |
|
|
Early-stage pre-clinical development of stabilized peptide-based antibacterial agents for difficult to treat multidrug resistant infections |
Biotide Solutions LLP |
|
|
Plasma Activated Water- A sustainable solution to Antimicrobial Resistance |
Indian Institute of Science Bangalore |